We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

BIOHIT Healthcare OY

  Silver Offers technologies and services for diagnosing and preventing gastrointestinal diseases and associated risks read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Biohit's GastroPanel Blood Test Accurately Diagnoses Hp Infection and AG Before Endoscopy

By LabMedica International staff writers
Posted on 09 May 2022
Print article
Image: GastroPanel test is meant for diagnosis of AG and Hp infection in patients referred for gastroscopy (Photo courtesy of Biohit Oyj)
Image: GastroPanel test is meant for diagnosis of AG and Hp infection in patients referred for gastroscopy (Photo courtesy of Biohit Oyj)

Helicobacter pylori (Hp) infection, atrophic gastritis (AG) and high acid output are important risk factors for gastric and esophageal cancers. Now, the latest study to evaluate the diagnostic accuracy of a unique blood test for the diagnosis of both AG and Hp infection in patients referred for gastroscopy from primary care with different indications has confirmed its high accuracy.

Biohit Oyj’s (Helsinki, Finland) new generation GastroPanel test is designed for the first-line diagnosis of Hp infection and AG in patients with upper abdominal symptoms, such as dyspepsia and gastro-oesophageal reflux disease (GORD), before endoscopy. GastroPanel is also the only test on the market capable of monitoring the regulatory mechanism of acid output in the stomach. The new generation (unified) GastroPanel test works on the same principle as the original GastroPanel ELISA test and is designed to harmonize the ELISA processing conditions of four biomarkers.

The highly informative GastroPanel assay is a cost-effective solution for population-based screening for the risk of gastric cancer in asymptomatic and symptomatic individuals, and its efficacy has already been confirmed by several studies in both high- and low-risk countries. Along with the previously published clinical validation studies, the latest biopsy-confirmed study was designed to verify the diagnostic capabilities of the new generation GastroPanel test compared to the current gold standard (gastroscopy and biopsy analysis), and to demonstrate its performance was comparable to the original GastroPanel test. The positive results from the study pave the way for BIOHIT’s new GastroPanel Quick Test (point of care test) which will be launched in Q1 2022.

“A total of 522 patients referred for gastroscopy at the Gastro Centre, OUH, were consented and enrolled for this particular study,” said Dr. Olli-Pekka Koivurova, Principal Investigator of the study. "Blood was sampled for all patients using the GastroPanel test, along with performing quality-controlled gastroscopies with mucosal biopsies. The results confirmed that the new generation GastroPanel is a highly accurate test for the non-invasive diagnosis of AG and Hp infection in patients referred for diagnostic gastroscopies.”

Related Links:
Biohit Oyj

Gold Supplier
Automatic Biochemistry Analyzer
Biossays C8
Automatic Immunoassay Analyzer
Automatic Hematology Analyzer
Microplate Reader

Print article


Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more


view channel
Image: The CS-2500 analyzer features pre-analytic sample checks and four detection methods simultaneously on a single platform – coagulation end-point, chromogenic kinetic analysis, turbidimetric immunoassay and automated platelet aggregation (Photo courtesy of Sysmex)

Microvascular/Endothelial Dysfunction Contributes to Post-COVID Syndrome Pathogenesis

Post-COVID syndrome (PCS) or Long-COVID is an increasingly recognized complication of acute SARS-CoV-2 infection, characterized by persistent fatigue, reduced exercise tolerance chest pain, shortness of... Read more


view channel
Image: Sales of lateral flow assays in clinical testing are expected to register a CAGR of 5% through 2032 (Photo courtesy of Pexels)

Global Lateral Flow Assays Market to Surpass USD 11.5 Billion by 2032 Due to Evolving Applications

The global lateral flow assays market was valued at USD 7.2 billion in 2021 and is projected to register a CAGR of 4.7% during 2022-2032 to surpass USD 11.7 billion by the end of 2032, driven by the growing... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.